Antithrombotic Treatment Resistance in Multiple Myeloma Likely Multifactorial
Researchers sought to determine the factors involved in the resistance to antithrombotic therapy that is observed among patients with multiple myeloma.
Myeloma
Dara-KRD Induction Effective in High-Risk, Newly Diagnosed Myeloma
The rate of minimal residual disease negativity was 62% after induction.
Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma
Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.
Factors Related to Adherence to Oral Multiple Myeloma Therapy
Researchers sought to identify socioeconomic and demographic factors related to adherence to oral therapies in patients with multiple myeloma.
Post-Transplant Carfilzomib, Lenalidomide, and Dexamethasone May Be New Standard of Care in Multiple Myeloma
Researchers sought to determine whether post-transplant carfilzomib, lenalidomide, and dexamethasone would have superior PFS in patients with multiple myeloma.
IKEMA Update Reveals “Unprecedented” PFS in Relapsed Multiple Myeloma
Adding isatuximab to carfilzomib and dexamethasone significantly improved progression-free survival at a median follow-up of 44 months.
Adaptation to Bortezomib Treatment in Multiple Myeloma Cells
Researchers sought to characterize features of multiple myeloma cells that may be involved in treatment resistance to bortezomib.
Academic BCMA CAR T-Cell Therapy “Promising” in Rel/Ref Multiple Myeloma
The overall response rate was 100%, and the 18-month progression-free survival rate was 53%.
ASCT Extends PFS in Newly Diagnosed Multiple Myeloma
Transplant after a 3-drug induction regimen can prolong progression-free survival, compared with triplet induction alone, in patients with multiple myeloma.
Mitigation Strategies Successfully Reduce Incidence of Adverse Effects After CAR-T With Ciltacabtagene Autoleucel
Researchers sought to identify predictors of movement and neurocognitive treatment-emergent adverse events in patients undergoing CAR-T therapy with ciltacabtagene autoleucel.
- Loading...
Loading...
Loading... 
Loading...